Shanghai Microport Medbot (group) Co., Ltd. Class H · HKEX:2252
Shanghai Microport Medbot (group) Co., Ltd. Class H — FY2025 Earnings Presentation
27 slides from Shanghai Microport Medbot (group) Co., Ltd. Class H's earnings presentation, March 2026
Slide 1: 2025 Annual Results Presentation
2025 Annual Results Presentation March 2026
Slide 2: Disclaimer
Disclaimer This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of Shanghai MicroPort MedBot (Group) Co., Ltd., and no part of it shall form the
Slide 3: Agenda
AGENDA Business Highlights Product Pipeline Update Financial Review Appendix 3
Slide 4: Financial Highlights
Financial Highlights Revenue Net Loss Free Cash Outflow ￥551.1mn ￥254.1mn ￥62.8mn +114% YoY Narrowed 61% YoY Improved 84% YoY overseas market RMB400mn, +287% YoY Adj Net Loss RMB165mn, - 66% YoY Achieved cash inflow in 2H25 Revenue by geographical area 2023-25 Revenue Growth (RMB million) (RMB milli
Slide 5: Business Highlights
Business Highlights ~300 accumulatively +220 units 65+ units 1 New orders for product Toumai® SkyWalkerTM orders portfolio >100 new orders in 2025 ~200 installed for >140 units >50 units 2 Installations product Toumai ® SkyWalkerTM units portfolio 80 units newly installed in 2025 Sales of instrument
Slide 6: Deepening Global Market Penetration with Strong Growth Momentum
Business Highlights Deepening Global Market Penetration with Strong Growth Momentum Global Approvals 60+ overseas approvals Russia Canada 10+ approvals for remote UK Netherland Poland Commercialized surgery Belgium Ukraine Installation Base France Switzerland Romania Uzbekistan Bulgaria (as of Mar 2
Slide 7: Accelerating Large-scale Surgeries across Products and Continents
Business Highlights Accelerating Large-scale Surgeries across Products and Continents Surgical procedures Toumai® SkyWalkerTM R-ONE ® Maintained No.1 in terms of clinical Assisted with 3,000+ TKA procedures 800+ PCI operations completed globally operations among domestic brands accumulatively 40+ op
Slide 8: World's 1st Approval – Ushering the Surgical Robot Industry into the Remote Era
Business Highlights World’s 1st Approval – Ushering the Surgical Robot Industry into the Remote Era Ruijin Hospital - A five-location World’s 1st satellite-based remote surgery conducted for robotic telesurgery and the first patients in Sanming (Fujian), Diqing remote surgery performed via low (Yunn
Slide 9: World's First and Only Company Approved across All Five Major Surgical Specialties
Business Highlights World’s First and Only Company Approved across All Five Major Surgical Specialties Toumai® Toumai® Toumai® Remote SkyWalkerTM UniPathTM Single-port Obtained approvals in ~40 Approved by NMPA in Feb 2025 Approved in 10+ countries or Accumulatively obtained Obtained NMPA approval i
Slide 10: Pioneering the Paradigm Shift in AI-integrated Intelligent Surgery
Business Highlights Pioneering the Paradigm Shift in AI-integrated Intelligent Surgery World's First Successfully completed the world's first animal trial of AI-powered Autonomous Surgery, powered by MicroGenius® Multimodal Autonomous surgical model Full-process Autonomy Marks a new stage where auto
Slide 11: Continued Operational Effectiveness Improvement
Business Highlights Continued Operational Effectiveness Improvement Optimizing Free Cash Outflow Gross profit Margin Net Loss Narrowed Operational Efficiency Decreased (RMB million) (RMB million) (RMB million) R&D S&M Admin 1,023.5 669.6 Improved 934.0 48.4% ~15 ppts 36.5% 37% 42% 126.4 39% 33.5% 23
Slide 12: Agenda
AGENDA Business Highlights Product Pipeline Update Financial Review Appendix 12
Slide 13: Comprehensive product offering covering all major surgical specialties
Product Pipeline Update Comprehensive product offering covering all 5 major and fast-growing surgical specialties Medical Device Surgical Product Clinical Trial/ Specialty Product Indicated Application Classification Design Development Design Validation Clinical Evaluation Registration Application I
Slide 14: Flagship product – Toumai Laparoscopic Surgical Robot
Product Pipeline Update Flagship product– Toumai® Laparoscopic Surgical Robot Multiple generations of Commercialization breakthrough Toumai® clinical progress • Obtained 100+ units of new order in overseas market in 2025, accumulatively ~170 units of order up to date, Covered 50+ countries/regions 2
Slide 15: Flagship product – SkyWalker Orthopedic Surgical Robot
Product Pipeline Update Flagship product – SkyWalkerTM Orthopedic Surgical Robot The 1st domestic surgical robot to expand into global market 2022 2023 2024 2025 China (NMPA) India China (NMPA, THA) Europe (CE, THA) US (FDA) Japan Brazil Thailand, Vietnam, Europe (CE) UK Australia Pakistan, Indonesi
Slide 16: UniPath Electronic Bronchoscopic Surgical Robot
Product Pipeline Update UniPathTM Electronic Bronchoscopic Surgical Robot Leverage the power of flexible robotics which uses a camera and tools to enter the lungs NMPA approval through their natural airways Precisely guide a biopsy instrument to those hard-to-reach nodules Cutting-edge Tech Strong M
Slide 17: R-ONE Vascular Interventional Robot System
Product Pipeline Update R-ONE® Vascular Interventional Robot System Designed to operate with precision and NMPA approval perform specific movements CE mark Facilitate and enhance the interventional procedures performed on the patient Clinical Performance Strong Commercialization Unique Synergy & Lea
Slide 18: Mona Lisa Robotic Transperineal Prostate Biopsy System
Product Pipeline Update Mona Lisa Robotic Transperineal Prostate Biopsy System NMPA Approval Real-time ultrasound images displayed on the monitor FDA Approval during the biopsy procedure CE Marking TGA Approval The surgeon manually inserts the needle into the prostate to collect the biopsy cores HAS
Slide 19: Strong industrial operation capabilities for surgical robots
Product Pipeline Update Strong industrial operation capabilities for surgical robots g pply chain eadin R&D 1,378 u L S Multilayered supply chain system applications In-house designed components 667 Scalable production of Toumai®, SkyWalkerTM and consumables granted (480 in China; 187 overseas) Annu
Slide 20: Agenda
AGENDA Business Highlights Product Pipeline Update Financial Review Appendix 20
Slide 21: Consolidated Financial Performance
Financial Review Consolidated Financial Performance REVENUE TOTAL NET LOSS FREE CASH FLOW Revenue reached RMB551m, up 114% YoY. Overseas Total net loss narrowed from 647.1m for the year ended 31 The successful implementation of revenue growth, strategic markets became our core growth engine, with To
Slide 22: Operating Expenses
Financial Review Operating Expenses R&D COST S&M EXPENSES ADMINISTRATIVE EXPENSES (RMB million) (RMB million) (RMB million) -62% -64% 228% -13% -46% -2% -56% -30% 207.9 569.2 238.4 -17% 203.6 126.4 308.7 81% 216.0 55.3 45.6 37% 2023 2024 2025 2023 2024 2025 2023 2024 2025 % Revenue R&D 216.0m, 30% d
Slide 23: In Closing
In Closing We delivered record revenue and robust momentum to drive continuous growth We enjoy large, global market opportunities Our comprehensive product pipeline enables technology integration, stimulates sales synergy, and provides integrated diagnostic and treatment solutions We are positioned
Slide 24: Agenda
AGENDA Business Highlights Product Pipeline Update Financial Review Appendix 24
Slide 25: Appendix I - Consolidated Balance Sheet
Appendix I - Consolidated Balance Sheet Unit: RMB'000 31 Dec 2025 31 Dec 2024 Var. Unit: RMB'000 31 Dec 2025 31 Dec 2024 Var. Non-current assets CAPITAL AND RESERVES Share capital 1,031,330 1,006,194 2% Property, plant and equipment 172,751 297,371 -42% Reserves (620,656) (727,992) -15% Intangible a
Slide 26: Appendix II - Consolidated P&L
Appendix II - Consolidated P&L Unit: RMB'000 2025 2024 Var. Revenue 551,069 257,249 114% Cost of sales (284,447) (171,029) 66% Gross profit 266,622 86,220 209% Other net income/(loss) 12,270 (3,168) -487% Selling and marketing expenses (203,608) (207,934) -2% Administrative expenses (45,637) (55,282
Slide 27: Thank You
a i bai " St SE @XOlNLE8A MedBot Surgical fj ; (RSS) (Twas)
Shanghai MicroPort MedBot (Group) — FY2025 Earnings Presentation on 6ix